	US 11,723,935 B2
	Methods and compositions for treating and diagnosing pancreatic cancers
George Miller, Englewood, NJ (US); Deepak Saxena, New York, NY (US); and Smruti Pushalkar, New York, NY (US)
Assigned to NEW YORK UNIVERSITY, New York, NY (US)
Appl. No. 16/484,080
Filed by New York University, New York, NY (US)
PCT Filed Feb. 6, 2018, PCT No. PCT/US2018/017052 § 371(c)(1), (2) Date Aug. 6, 2019, PCT Pub. No. WO2018/145082, PCT Pub. Date Aug. 9, 2018.
Claims priority of provisional application 62/455,424, filed on Feb. 6, 2017.
Prior Publication US 2020/0113951 A1, Apr. 16, 2020
Int. Cl. A61K 35/742 (2015.01); A61K 9/00 (2006.01); A61K 35/745 (2015.01); A61K 35/747 (2015.01); A61P 35/00 (2006.01)

CPC A61K 35/742 (2013.01) [A61K 9/0019 (2013.01); A61K 35/745 (2013.01); A61K 35/747 (2013.01); A61P 35/00 (2018.01)]

14 Claims

1. A method for treating a pancreatic cancer or pancreatic tumor in a subject in need thereof, said method comprising administering to the subject an effective amount of one or more probiotic compositions comprising one or more strains of bacteria from species Akkermansia muciniphila and one or more strains of bacteria from species Lactobacillus reuteri and further comprising administering a programmed cell death protein 1 (PD-1) inhibitor.